Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-04-04

Clinical Trial Update: CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates for CD24Fc (TIRAEC study) in advanced solid tumors show termination after Phase 1/2 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CD24Fc

Snippet

Sponsor: Tianhong Li | Conditions: Advanced Malignant Solid Neoplasm | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-04-04